Gastrointestinal Cancer

Pathologists and laboratory professionals are key members of the multidisciplinary cancer care team, with roles in the diagnosis, testing, and management of diseases such as gastrointestinal cancer. As new evidence continues to emerge related to personalized testing, treatment, and reporting, ASCP is dedicated to helping you stay abreast of new findings to ensure accurate diagnoses and improve the standard of care for patients with gastrointestinal cancer.

CME Workshops

COMBINED: Collaboration of Multidisciplines for Biomarker Testing Implementation Needed for Effective Treatment Decisions in mCRC

Hosted in Partnership With The France Foundation and Association of Community Cancer Centers

During these live workshops expert faculty will provide guidance for the multidisciplinary colorectal cancer (CRC) care team on how to develop practical biomarker testing protocols for metatstatic CRC (mCRC), and how this information supports personalized treatment decisions for improved patient outcomes. You’ll walk away with a better understanding of:

The latest guideline recommendations regarding biomarker testing in mCRC
When biomarker testing should be performed, including the process/protocols and the role of the multidisciplinary team
The need for biomarker testing to guide individualized therapy decisions
Targeted therapeutic options for the treatment of mCRC and how to identify their utilization in appropriate patients
The role of CRC care team members and different techniques for increased communication and collaboration

Learn More

Join us at the COMBINED events in the following cities:

Houston, TX | Fri, September 22, 2023, 9:00 a.m.–1:30 p.m. CDT

Philadelphia, PA | Fri, October 20, 2023, 8:30 a.m.–1:00 p.m. EDT

Detroit, MI | Sat, November 4, 2023, 9:00 a.m.–1:30 p.m. EST

Atlanta, GA | Sat, November 11, 2023, 9:00 a.m.–1:30 p.m. CST

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation, American Society for Clinical Pathology, and Association of Community Cancer Centers.

In support of improving patient care, this activity has been planned and implemented by The France Foundation, American Society for Clinical Pathology, and Association of Community Cancer Centers. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physician Credit Designation
This live activity is designated for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 4.5 contact hours.

All other healthcare professionals completing this course will be issued a statement of participation.

This project is provided by an educational grant from Pfizer.

HEPATIC: HCC Education and Protocols to Advance Treatment Through Integrated Collaboration

Hosted in Partnership With The France Foundation, Association of Community Cancer Centers, and Society of Interventional Oncology

During these live workshops expert faculty will provide guidance for the multidisciplinary hepatocellular carcinoma (HCC) care team on how to analyze the latest clinical information and improve their confidence in providing the most accurate recommendations for treatment in all stages of HCC. You’ll walk away with a better understanding of:

Strategies for early and accurate diagnosis of HCC stages
MOA and clinical profiles of new and emerging IO agents (mono and combo) for each stage of HCC
Data on IO therapy with ADT procedures to identify appropriate patients
How to formulate a plan for discussions with patients around their care plans
The role of HCC care team members and different techniques for increased communication and collaboration

Learn More

Join us at the HEPATIC events in the following cities:

San Diego, CA | Saturday, August 26, 2023, 8:30 a.m.–1:00 p.m. PDT

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation, American Society for Clinical Pathology, Society of Interventional Oncology, and Association of Community Cancer Centers.

In support of improving patient care, this activity has been planned and implemented by The France Foundation, American Society for Clinical Pathology, Society of Interventional Oncology, and Association of Community Cancer Centers. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Nurses: The France Foundation designates this activity for 4.5 contact hours.

All other healthcare professionals completing this course will be issued a statement of participation.

This project is provided by an educational grant from AztraZeneca.

Online Modules

Diagnostic Pitfalls and Challenges in Hepatocellular Carcinoma

This one-hour CME/CMLE credit-bearing case-based online module will provide the latest guidance to the laboratory team in providing the most accurate recommendations for testing as members of the multidisciplinary hepatocellular carcinoma (HCC) cancer treatment team.

This activity addresses the following topics:

Liver tissue acquisition
HCC diagnostic challenges
IHC and ISH staining techniques to resolve common differential diagnoses
HCC biomarkers

Faculty

Jingmei Lin, MD, PhD, FASCP
Professor and Director of GI and Liver Pathology
Department of Pathology and Laboratory Medicine
Indiana University

Rondell P. Graham, MBBS
Professor of Lab Medicine and Pathology
Head of Section of GI/Liver Pathology
Vice Chair of Test Development for the Department of Lab Medicine and Pathology
Mayo Clinic

Watch Video

Biomarker Testing in Colorectal Cancer

This one-hour CME/CMLE credit-bearing activity will provide guidance to members of the laboratory team on how to develop and implement guideline-driven biomarker testing protocols for patients with metastatic colorectal cancer (mCRC).

This activity addresses the following topics:

NCCN guidelines for biomarker testing for patients with mCRC
Considerations to optimize fixation, IHC, and molecular testing in patients with mCRC
Techniques for optimizing the interpretation and communication of biomarker testing results
New and emerging therapies for patients with mCRC
The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

Faculty

Benjamin Swanson, MD, PhD
Associate Professor & Associate Director
Gastrointestinal Pathology Fellowship
University of Nebraska Medical Center

Wei Jiang, MD, PhD
Associate Professor & Director, Translational Research/Pathology Shared Resource of Sidney Kimmel Cancer Center
Thomas Jefferson University

This project is provided by an educational grant from Pfizer.

Online Tumor Board Simulation: Optimizing Testing and Treatment of Patients with BRAF^V600E-mutant mCRC in Community Practice

This 60-minute self-paced online tumor board will help pathologists and laboratory professionals, particularly those in community practice, gain deeper scientific knowledge and skills in diagnosing, testing, and treating patients with BRAF-mutant metastatic colorectal cancer (mCRC). Throughout the online tumor board simulation, learners will answer questions designed to help them carefully consider the nuances of each case, building their knowledge and skills related to the detection and optimal management of patients with BRAF-mutant mCRC.

Topics covered include the following:

NCCN guidelines for conducting biomarker testing, including BRAF testing, for patients with mCRC
The importance of conducting biomarker testing at the time of diagnosis
Considerations to optimize fixation and IHC and molecular testing for BRAF mutations in patients with mCRC
Interpretation and communication of BRAF testing results
Opportunities for improving turnaround time in molecular testing in mCRC, including current and emerging testing platforms
Clinicopathologic characteristics of BRAF-mutant mCRC
New and emerging therapies for patients with BRAF-mutant mCRC
The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

The activity offers 1.0 CME/CMLE credit.

Faculty:

Wei Jiang, MD, PhD, FASCP
Associate Professor
Director, Translational Research/Pathology
Shared Resource of Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

Atrayee Basu-Mallick, MD
Associate Professor
Medical Oncology
Jefferson Health/Jefferson University Hospitals
Philadelphia, PA

This activity is supported by educational grants from Lilly and Pfizer.

Multidisciplinary Approach to Diagnosis and Biomarker Testing in Gastrointestinal Cancer

Recorded February 15, 2022

This 60-minute on-demand webcast highlights practice-changing developments in gastrointestinal biomarker testing and treatment, including new clinical data with immediate implications for patient care. Using a case-based approach, an expert GI pathologist and oncologist will help you learn optimal testing, interpreting findings, individualized treatment, and sequencing strategies for gastrointestinal cancers.

Faculty:

Wei Jiang, MD, PhD, FASCP
Associate Professor
Director, Translational Research/Pathology Shared Resource of
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA

Atrayee Basu-Mallick, MD
Associate Professor
Medical Oncology
Jefferson Health/Jefferson University Hospitals
Philadelphia, PA

Topics include:

Biomarkers and the use of molecular testing to guide therapy selection in patients with advanced colorectal, pancreatic, biliary, gastric, esophageal, and gastroesophageal junction cancers, such as:
- BRAF V600E, BRCA1/2, HER2/HER3, BRAF V600E, IDH1, and FGFR2
- Tumor agnostic biomarkers, such as MMR/MSI, NTRK, and TMB
- Emerging biomarkers
Emerging assays in GI cancers, such as liquid biopsy

Download Slideset

Download Clinical Commentary

Provided by American Society of Clinical Pathology in partnership with Clinical Care Options, LLC.

Supported by educational grants from Pfizer Inc. and Seagen Inc.

Gastrointestinal Cancer

Register for COMBINED CME Workshops

Register for HEPATIC CME Workshops

Online Modules

First Name		*
Last Name		*
Email		*
Customer ID